Senti Bio to Showcase SENTI-202 Clinical Data and Novel Logic Gated Gene Circuit Mechanism of Action in Oral and Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2025

Rhea-AI Summary

Senti Biosciences (NASDAQ: SNTI) announced three abstract presentations at the upcoming AACR Annual Meeting 2025 (April 25-30, Chicago), showcasing new data from their lead product SENTI-202, a CAR NK cell therapy for relapsed/refractory acute myeloid leukemia (r/r AML).

The presentations include an oral minisymposium on clinical data, and two poster sessions focusing on correlative data and preclinical characterization of their Logic Gate technology. The preclinical data demonstrates that EMCN inhibitory CAR (NOT gate) effectively protects healthy bone marrow cells from on-target off-tumor toxicity in vivo.

Dr. Kanya Rajangam, President, Head of R&D and Chief Medical Officer, emphasized the potential of SENTI-202 for treating r/r AML and highlighted the broader applications of Logic Gating technology in oncology for selective cancer targeting while preserving healthy cells.

Positive

• First-in-human clinical trial data presentation for lead product SENTI-202
• Preclinical data shows successful protection of healthy cells while targeting cancer
• Multiple data presentations (clinical, correlative, preclinical) at major cancer conference

Negative

• None.

Insights

Biotechnology Analyst

Senti Bio's upcoming presentations at AACR 2025 mark a critical milestone in the company's clinical development of SENTI-202, its lead candidate targeting relapsed/refractory acute myeloid leukemia (r/r AML). Most significantly, this will include first-in-human clinical data from their ongoing trial, which investors have been eagerly awaiting.

The selection for an oral minisymposium rather than just poster presentations is particularly noteworthy, as these slots are typically reserved for more impactful clinical findings. This suggests the data may demonstrate meaningful clinical activity, though specific efficacy signals remain unrevealed.

What makes SENTI-202 scientifically distinctive is its logic-gated approach - specifically the CD33 OR FLT3 NOT EMCN gene circuit. Unlike conventional CAR therapies that target single antigens and risk significant off-tumor toxicity, this design allows targeting of multiple AML-associated antigens (CD33 and FLT3) while using EMCN as an inhibitory signal to protect healthy hematopoietic stem cells. The preclinical data being presented appears to validate this mechanism, showing protection of healthy bone marrow cells from toxicity.

For a clinical-stage biotech with a $83M market cap, these presentations represent crucial validation points for both their lead program and underlying platform technology. However, investors should remain cautious as this represents early clinical data, and the true value proposition depends on efficacy and safety outcomes that haven't yet been disclosed.

Hematology-Oncology Specialist

The upcoming SENTI-202 data presentations warrant attention as they address a significant unmet medical need in r/r AML, a disease with historically poor outcomes and effective therapies. The first-in-human clinical data will provide our first genuine look at whether Senti's innovative logic-gating approach translates from promising preclinical models to actual patient responses.

What distinguishes SENTI-202 is its dual-targeting CD33/FLT3 approach combined with EMCN inhibitory signaling. AML remains challenging to treat because targeting leukemic stem cells often damages healthy hematopoietic stem cells (HSCs). The NOT gate technology, if successful, could represent a meaningful advancement by preserving healthy HSCs while eliminating malignant cells.

The presentation of correlative data is particularly important as it will likely show whether the CAR-NK cells are properly trafficking, persisting, and maintaining their intended selectivity profile in patients. The humanized mouse model data should provide supporting evidence for the mechanism's functionality.

AML patients face a 25-30% five-year survival rate in the relapsed/refractory setting, so clinicians will be scrutinizing this data for signals of improved outcomes. However, as an early clinical program, we should expect primarily safety and pharmacokinetic data rather than definitive efficacy signals. The specific design aspects presented may also provide insights into whether this platform could be applied to other hematologic malignancies beyond AML, potentially expanding Senti's therapeutic opportunities.

New data to be presented from Company’s lead product candidate SENTI-202 for the treatment of relapsed/refractory acute myeloid leukemia (r/r AML) development program

SOUTH SAN FRANCISCO, Calif., April 03, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that three abstracts have been selected for an oral minisymposium and poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2025, taking place April 25-30, 2025, at the McCormick Place Convention Center in Chicago, IL.

Kanya Rajangam, MD, PhD, President, Head of R&D and Chief Medical Officer of Senti Bio commented, “We are excited to present updated clinical and correlative data from our ongoing SENTI-202 trial, along with detailed preclinical characterization of our Logic Gate technology. The preclinical data shows the EMCN inhibitory CAR (our NOT gate) protects healthy bone marrow cells from on-target off-tumor toxicity in vivo. Taken together, this data continues to support our enthusiasm for the potential of SENTI-202 to treat r/r AML and for Logic Gating, including our unique NOT gates, to be broadly applied to oncology to enhance the selective targeting of cancer while sparing healthy cells that may express the same targets.”

Details of the accepted abstracts are as follows:

Title: First-in-human, multicenter study of SENTI-202, a CD33/FLT3 selective off-the-shelf logic gated CAR NK cell therapy in hematologic malignancies including AML: Clinical data
Session Type: Clinical Trials Oral Minisymposium
Session Title: CTMS01 - ADCs and Immunooncology-focused Biological Approaches
Date and Time: Sunday, April 27, 2025 at 4:30 PM CST
Location: To be Announced
Abstract Number: CT041

Title: First-in-human, multicenter study of SENTI-202, a CD33/FLT3 selective off-the-shelf logic gated CAR NK cell therapy in hematologic malignancies including AML: Correlative data
Session Type: Poster Session
Session Title: PO.CT01.02 - First-in-Human Phase I Clinical Trials 2
Date and Time: Tuesday, April 29, 2025 from 9:00 AM- 12:00 PM CST
Location: Section 48
Abstract Number: CT143 / 9

Title: SENTI-202 CD33 OR FLT3 NOT EMCN logic-gated gene circuit components selectively target AML while protecting human HSC/HPCs from off-tumor toxicity in a humanized mouse model
Session Type: Poster Session
Track: Immunology
Session Title: PO.IM01.17 - Novel In Vivo, In Vitro, and In Silico Models
Date and Time: Wednesday, April 30, 2025 from 9:00 AM - 12:00 PM CT
Location: Section 38
Abstract Number: 7271 / 18

For more information, please visit the AACR Annual Meeting website.

About Senti Bio

Senti Bio is a clinical-stage biotechnology company developing a new generation of cell and gene therapies for patients living with incurable diseases. To achieve this, Senti Bio is leveraging a synthetic biology platform called Gene Circuits to create therapies with enhanced precision and control. These Gene Circuits are designed to precisely kill cancer cells, spare healthy cells, increase specificity to target cells and control the expression of drugs even after administration. Senti Bio’s wholly-owned pipeline includes off-the-shelf CAR-NK cells, outfitted with Gene Circuits, to target challenging liquid and solid tumor indications. Senti Bio’s lead program SENTI-202, a Logic Gated CD33 and/or FLT3-targeting hematologic cancer therapeutic candidate, demonstrated MRD-negative complete remissions in 2 of 3 patients in initial clinical data as of September 19, 2024, with 6+ month durability as of March 20, 2025. Senti Bio has also preclinically demonstrated that its Gene Circuits can function in T cells, for example Logic Gates that enable selective targeting of solid tumors. Additionally, Senti Bio has preclinically demonstrated the potential breadth of Gene Circuits in other cell and gene therapy modalities, diseases outside of oncology, and continues to advance these capabilities through partnerships.

Forward-Looking Statements

This press release contains certain statements that are not historical facts and are considered forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements generally are identified by the words “believe,” “could,” “predict,” “continue,” “ongoing,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” “forecast,” “seek,” “target” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Forward-looking statements are predictions, projections, and other statements about future events that are based on current expectations of Senti Bio’s management and assumptions, whether or not identified in this document, and, as a result, are subject to risks and uncertainties. Forward-looking statements include, but are not limited to, statements regarding future events, including the future development of our clinical and pre-clinical pipeline, success of our SENTI-202 clinical trial and financial projections and future financial and operating results. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as and must not be relied on by any investor as, a guarantee, an assurance, a prediction, or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of Senti Bio. Many factors could cause actual future results to differ materially from the forward-looking statements in this document, including but not limited to: (i) changes in domestic and foreign business, market, financial, political and legal conditions, (ii) changes in the competitive and highly regulated industries in which Senti Bio operates, variations in operating performance across competitors, changes in laws and regulations affecting Senti Bio’s business, (iii) the ability to implement business plans, forecasts and other expectations, (iv) the risk of downturns and a changing regulatory landscape in Senti Bio’s highly competitive industry, (v) risks relating to the uncertainty of any projected financial information with respect to Senti Bio, (vi) risks related to uncertainty in the timing or results of Senti Bio’s clinical trial initiation and the progress of clinical trials, patient enrollment, and GMP manufacturing activities, (vii) Senti Bio’s dependence on fourth parties in connection with clinical trial startup, clinical studies, and GMP manufacturing activities, (viii) risks related to delays and other impacts from macroeconomic and geopolitical events, increasing rates of inflation and rising interest rates on business operations, (ix) risks related to the timing and utilization of Senti Bio’s grant from CIRM and net proceeds of the PIPE financing, and (x) the success of any future research and development efforts by Senti Bio. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of Senti Bio’s most recent Quarterly Report on Form 10-Q, filed with the U.S. Securities and Exchange Commission (“SEC”), and other documents filed by Senti Bio from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements in this document. There may be additional risks that Senti Bio does not presently know, or that Senti Bio currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements in this document. Forward-looking statements speak only as of the date they are made. Senti Bio anticipates that subsequent events and developments may cause Senti Bio’s assessments to change. Except as required by law, Senti Bio assumes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events, or otherwise.

Investor Contact:
JTC Team, LLC
Jenene Thomas
(908) 824-0775
SNTI@jtcir.com

FAQ

What is SENTI-202 and what cancer type does it target?

SENTI-202 is a CD33/FLT3 selective off-the-shelf logic gated CAR NK cell therapy targeting relapsed/refractory acute myeloid leukemia (r/r AML).

When and where will Senti Bio (SNTI) present their SENTI-202 clinical data?

Senti Bio will present at the AACR Annual Meeting 2025, April 25-30, at McCormick Place Convention Center in Chicago, with the clinical data presentation scheduled for April 27, 2025.

How does SENTI-202's Logic Gate technology protect healthy cells?

SENTI-202 uses EMCN inhibitory CAR (NOT gate) technology that protects healthy bone marrow cells from on-target off-tumor toxicity while selectively targeting cancer cells.

What types of data will SNTI present for SENTI-202 at AACR 2025?

SNTI will present three types of data: clinical trial results in an oral minisymposium, correlative data, and preclinical characterization of their Logic Gate technology in poster sessions.